Baxter International Inc. (BAX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Baxter International Inc. (BAX) Healthcare & Pipeline Overview

Baxter International Inc. is a global healthcare company providing a diverse portfolio of products, including dialysis therapies, intravenous solutions, and surgical products. With a presence in approximately 100 countries, Baxter serves hospitals, dialysis centers, and patients at home, competing in the medical instruments and supplies sector.

What Is the Investment Thesis for BAX?

Baxter International Inc. presents a mixed investment thesis. The company's diverse product portfolio and global presence offer stability, as evidenced by its established position in dialysis therapies and intravenous solutions. The dividend yield of 2.00% provides income for investors. However, the negative profit margin of -9.7% raises concerns about profitability. Future growth depends on Baxter's ability to innovate and expand its product offerings, particularly in connected care solutions and surgical products. Investors should monitor the company's progress in improving profitability and capitalizing on growth opportunities in the healthcare sector. The company's agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules may provide future catalysts.

Based on FMP financials and quantitative analysis

BAX Key Highlights

Market capitalization of $12.5B reflects Baxter's established position in the healthcare industry.

• Gross margin of 30.1% indicates the company's ability to manage production costs, although it could be improved.
• Dividend yield of 2.00% provides a steady income stream for investors.
• Beta of 0.62 suggests lower volatility compared to the overall market.
• Presence in approximately 100 countries demonstrates Baxter's global reach and diversified revenue streams.

Who Are BAX's Competitors?

BAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BAX's Key Strengths?

Diverse product portfolio across multiple healthcare segments.

• Global presence with operations in approximately 100 countries.
• Established relationships with hospitals, dialysis centers, and other healthcare providers.
• Strong brand reputation in the healthcare industry.

What Are BAX's Weaknesses?

Negative profit margin of -9.7% indicates profitability challenges.

• Dependence on traditional product lines may limit growth potential.
• Exposure to regulatory risks and pricing pressures in the healthcare industry.
• High debt levels may constrain investment opportunities.

What Could Drive BAX Stock Higher?

BAX catalyst: Potential positive impact from the agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules.

• Expansion of connected care solutions and remote patient monitoring services.
• Growth in emerging markets with increasing healthcare expenditure.
• Development and launch of new products in the dialysis, intravenous solutions, and surgical product segments.

What Are the Key Risks for BAX?

Negative return on equity (-16.4%) — the business is not currently generating profit on shareholder capital.

• Insider selling — insiders were net sellers of roughly $1.5M recently.
• Intense competition from other medical device and healthcare companies.
• Pricing pressures and reimbursement challenges in the healthcare industry.
• Regulatory changes and compliance requirements.
• Product liability claims and recalls.
• Negative profit margin of -9.7% indicates profitability challenges.

What Are the Growth Opportunities for BAX?

• Expansion in Connected Care Solutions: Baxter can capitalize on the growing demand for connected care solutions, including remote patient monitoring and telehealth. The market for remote patient monitoring is projected to reach $55 billion by 2027. By developing and integrating advanced technologies into its existing product portfolio, Baxter can improve patient outcomes, reduce healthcare costs, and gain a competitive advantage. Timeline: Ongoing.
• Growth in Emerging Markets: Baxter has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical products is increasing. By tailoring its product offerings to meet the specific needs of these markets and establishing strategic partnerships with local distributors, Baxter can drive revenue growth and increase its global market share. Timeline: Ongoing.
• Development of Innovative Dialysis Therapies: Baxter can invest in the development of innovative dialysis therapies to improve the quality of life for patients with kidney failure. The global dialysis market is expected to reach $105 billion by 2028. By developing more effective and convenient dialysis solutions, Baxter can strengthen its position in the dialysis market and attract new customers. Timeline: Ongoing.
• Strategic Acquisitions and Partnerships: Baxter can pursue strategic acquisitions and partnerships to expand its product portfolio and enter new therapeutic areas. By acquiring companies with complementary technologies and expertise, Baxter can accelerate its innovation efforts and strengthen its competitive position. Timeline: Ongoing.
• Focus on Surgical Products: Baxter can focus on expanding its surgical product offerings, including hemostasis, tissue sealing, and adhesion prevention products. The market for surgical products is expected to grow due to the increasing number of surgical procedures performed worldwide. By developing and marketing advanced surgical products, Baxter can increase its revenue and profitability. Timeline: Ongoing.

What Are BAX's Competitive Advantages?

• Established brand reputation in the healthcare industry.
• Diverse product portfolio with a wide range of therapies and solutions.
• Global presence with sales in approximately 100 countries.
• Strong relationships with hospitals, dialysis centers, and other healthcare providers.

What Does BAX Do?

Baxter International Inc. was founded in 1931 and has evolved into a global healthcare leader. The company develops, manufactures, and markets a wide range of products and services used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. Baxter's product portfolio includes peritoneal dialysis and hemodialysis therapies, intravenous solutions, infusion pumps, and drug reconstitution devices. It also offers remixed and oncology drug platforms, inhaled anesthesia, critical care products, and pharmacy compounding services. Additionally, Baxter provides parenteral nutrition therapies, biological products, and medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention. The company's connected care solutions encompass devices, software, communications, and integration technologies, including patient monitoring and diagnostic tools. Baxter sells its products through a direct sales force and independent distributors in approximately 100 countries. Headquartered in Deerfield, Illinois, Baxter continues to innovate and expand its offerings to meet the evolving needs of the healthcare industry.

What Products and Services Does BAX Offer?

• Develops and provides peritoneal dialysis and hemodialysis therapies.
• Offers intravenous therapies, infusion pumps, and drug reconstitution devices.
• Provides remixed and oncology drug platforms, inhaled anesthesia, and critical care products.
• Offers pharmacy compounding services and parenteral nutrition therapies.
• Manufactures biological products and medical devices for surgical procedures.
• Provides connected care solutions, including devices, software, and integration technologies.
• Offers contracted services to pharmaceutical and biopharmaceutical companies.

How Does BAX Make Money?

• Develops and manufactures a wide range of healthcare products.
• Sells products through a direct sales force and independent distributors.
• Generates revenue from the sale of dialysis therapies, intravenous solutions, and surgical products.
• Provides contracted services to pharmaceutical and biopharmaceutical companies.

What Industry Does BAX Operate In?

Baxter International Inc. operates in the medical instruments and supplies industry, a segment of the broader healthcare sector. The industry is characterized by continuous innovation, increasing demand for advanced medical technologies, and stringent regulatory requirements. Key trends include the growing adoption of connected care solutions, the rising prevalence of chronic diseases such as kidney failure, and the increasing focus on cost-effectiveness in healthcare delivery. Baxter competes with companies like Madrigal Pharmaceuticals, Inc. (MDGL), DaVita Inc. (DVA), Masimo Corporation (MASI), AptarGroup, Inc. (ATR), and Qiagen N.V. (QGEN). The industry is expected to grow due to the aging global population and increasing healthcare expenditure.

Who Are BAX's Key Customers?

• Kidney dialysis centers
• Nursing homes
• Rehabilitation centers
• Doctors' offices
• Patients at home under physician supervision

Baxter International Inc. Financial Trajectory

Baxter International Inc. (BAX) reported $2.96B in revenue for Jun 2026, reflecting 9.6% growth compared to the prior quarter. The company recorded net income of $126.0M, with diluted EPS of $0.24. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BAX averaged $-0.52 in diluted EPS.

Company Profile

Baxter International Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Deerfield, US. The company is led by CEO Andrew Hider. BAX has traded publicly since 1981.

How Baxter International Inc. Is Valued

Baxter International Inc. carries a market capitalization of $12.5B, placing it in the large-cap category. Analyst price targets span from $21.00 to $28.00, with a consensus of $25.00. At the current price of $24.18, that implies approximately 3% upside potential. Relative to its peer group, BAX's quantitative score of 53/100 is roughly in line with the peer average of 57/100.

Return on equity for Baxter International Inc. stands at -16.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.5%, the inverse of the P/E and a quick read on earnings relative to price.

Baxter International Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.28 places it in the grey zone, a middle ground that warrants monitoring.

Baxter International Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 11.4% above estimates on average.

Wall Street analysts project Baxter International Inc. revenue of about $11.61B for fiscal 2026, with EPS near $2.05. The estimate reflects 10 contributing analysts.

Over the past six months, Baxter International Inc. insiders filed 11 SEC Form 4 transactions — 3 sales and 8 purchases. On net that is roughly 46K shares acquired (about $1.5M) — insiders putting money in tends to read as conviction.

BAX Financials

BAX Latest News

BAX Analyst Consensus

BAX MoonshotScore

Latest Baxter International Inc. Analysis

What Investors Ask About Baxter International Inc. (BAX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources